Plain-English translation of NCT07288138 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing and —two experimental medications—to see if they can reduce fat buildup in the liver in people with a condition called MASH (metabolic dysfunction-associated steatohepatitis). The study will compare these medications at different doses, alone and in combination, against a placebo to find out which approach works best and is safest.
MASH is a serious liver condition caused by fat accumulation, and currently there are very few approved treatments. This study aims to find out whether this medication could help reduce liver fat and slow the disease's progression.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either a placebo or one of the study medications at different doses for 12 weeks. During this time, you'll have regular visits where doctors will check your liver health using blood tests and imaging scans (MRI). The main goal is to measure changes in liver fat using a special MRI scan, and researchers will also monitor your safety and any side effects throughout the study.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States